Not FDA-approved · Research compound · Used in Russian rheumatology and sports medicine practice
Human evidence
Moderate for a bioregulator — Russian clinical data in osteoarthritis patients; functional outcome and pain reduction data available
Preclinical evidence
Strong — chondrocyte gene expression, cartilage matrix preservation, and anti-inflammatory effects across multiple models
EDUCATIONAL TOOL — NOT MEDICAL ADVICE
What is Sigumir?
Sigumir is a natural cartilage and bone peptide Cytomax — the full spectrum of peptides extracted from calf cartilage tissue. Developed by Professor Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology, it is the musculoskeletal entry in the bioregulator system, targeting the chondrocytes (cartilage-producing cells) and osteoblasts (bone-forming cells) that maintain joint and skeletal integrity.
Cartilage is avascular — it has no blood supply of its own and relies entirely on diffusion from surrounding synovial fluid for nutrition. This makes it uniquely vulnerable to aging: once damaged, cartilage regenerates slowly and incompletely. Chondrocytes become increasingly senescent with age, reducing their production of collagen II, aggrecan, and other matrix components that give cartilage its load-bearing properties. The result is the progressive joint degeneration that makes osteoarthritis one of the most common disabling conditions in older adults.
Sigumir is designed to address this at the cellular level — not by providing substrate (like collagen supplements) or suppressing inflammation (like NSAIDs), but by signaling chondrocytes to maintain their anabolic gene expression programs as they age.
How it works
Chondrocyte Chromatin Interaction
Following the Khavinson bioregulator model, Sigumir's cartilage peptide complex is proposed to interact with chromatin in chondrocytes — regulating gene expression programs specific to cartilage tissue. The natural Cytomax form provides the full spectrum of these short signaling peptides, which Khavinson's group argues produces broader coverage of chondrocyte gene regulatory targets than any single synthetic sequence could.
Cartilage Matrix Gene Upregulation
Cell studies show Sigumir upregulates expression of collagen type II (the primary structural protein of hyaline cartilage), aggrecan (the proteoglycan responsible for cartilage's water-retaining and compressive properties), and Sox9 (the master transcription factor for chondrocyte identity and matrix production). These are exactly the genes that downregulate in aging and osteoarthritic chondrocytes.
Anti-Inflammatory and Anti-Catabolic Effects
Sigumir reduces expression of matrix metalloproteinases (MMPs) — the enzymes responsible for breaking down cartilage matrix in inflammatory conditions. It also modulates IL-1β and TNF-α signaling in synovial tissue, reducing the inflammatory drive to cartilage degradation. This dual anabolic (build matrix) + anti-catabolic (reduce breakdown) profile is mechanistically important.
Bone Remodeling Support
As a combined cartilage and bone Cytomax, Sigumir also influences osteoblast and osteoclast activity — the cells responsible for bone formation and resorption. Research suggests improved bone mineral density markers and reduced osteoclast activity in animal models, making Sigumir relevant for osteoporosis prevention as well as cartilage health.
What the research shows
STRONGER CLINICAL EVIDENCE THAN MOST BIOREGULATORS — OSTEOARTHRITIS PATIENT DATA AVAILABLE
STUDYJournal of Bioregulatory and Homeostatic Agents · 2009
Sigumir in Osteoarthritis — Pain, Function, and Cartilage Biomarkers
Khavinson VK et al.
Patients with knee osteoarthritis receiving Sigumir showed statistically significant improvements in WOMAC pain scores, functional assessment, and reduced morning stiffness vs. controls at 6-month follow-up. Serum cartilage oligomeric matrix protein (COMP) — a marker of cartilage degradation — was reduced in the treatment group.
STUDYBulletin of Experimental Biology and Medicine · 2006
Cartilage Peptide Complex Effects on Chondrocyte Gene Expression
Khavinson VK et al.
Sigumir increased expression of collagen II, aggrecan, and Sox9 in human chondrocyte cell culture — the core anabolic matrix genes that decline in aging and osteoarthritic cartilage. MMP-13 (major cartilage-degrading enzyme) expression was concurrently reduced. Effects were most pronounced in cells from older donors.
Elderly patients (65–75 years) receiving Sigumir showed improved bone mineral density scores and reduced osteocalcin/CTX-1 ratio (indicating more formation vs. resorption) vs. controls after two annual courses. Authors proposed dual chondrocyte + osteoblast gene regulation as the mechanism.
Sigumir has unusually high biohacker popularity for an organ-specific bioregulator because joint health is a near-universal concern in active aging populations. Unlike many bioregulators where the benefit is systemic and hard to perceive directly, joint pain and mobility are immediately felt — making Sigumir's effects easier to subjectively evaluate.
Community protocols follow Khavinson's clinical approach: 5–10 mg/day SC for 10 days, 2–3 courses per year. Protocols typically run it alongside Bonomarlot (bone marrow Cytomax) and Gotratix (muscle Cytomax) for a complete structural package — the Structural/Athletic stack from the hub. Athletes with repetitive joint load often run 3 courses per year; older adults with early osteoarthritis typically do 2.
A common combination is Sigumir + BPC-157 for joint repair — using Sigumir for the chondrocyte signaling component and BPC-157 for local tissue repair and tendon healing. These are complementary mechanisms with no known interactions.
WHAT THE RESEARCH SHOWS
✓KNOWN
✓Sigumir is a natural cartilage Cytomax — full spectrum of chondrocyte-regulating peptides from calf cartilage
✓Cell studies show upregulation of collagen II, aggrecan, Sox9, and reduction of MMP-13 — exactly the gene expression changes needed to counter cartilage aging
✓Russian clinical data in osteoarthritis patients shows pain reduction, functional improvement, and reduced cartilage degradation markers (COMP)
✓Bone mineral density data from elderly subjects shows improvement over two annual courses
✓Well-tolerated — Cytomax formulations have 30+ years of clinical use with no serious adverse events documented
?UNCERTAIN
?Whether Sigumir produces measurable cartilage benefit in younger people (under 45) without existing joint pathology
?Whether functional improvements in osteoarthritis patients translate to structural cartilage preservation on MRI — outcome data is clinical, not imaging
?Independent Western-standard RCT data — all clinical evidence is from Khavinson group Russian studies
?Optimal course frequency for different disease stages — 2 vs. 3 courses per year is not formally compared
?Whether Sigumir (Cytomax) or a Cytogen equivalent produces superior outcomes for targeted chondrocyte signaling
RECONSTITUTION CALCULATOR
EDUCATIONAL TOOL — NOT MEDICAL ADVICE · VERIFY WITH YOUR CLINICIAN
AI COACH PREVIEW
I'm 48, active, and starting to feel early knee wear — some stiffness after training and occasional grinding. I want to use Sigumir preventively. How do I run it and what else should I stack with it?
At your stage — early wear, still active — Sigumir makes a lot of sense. The goal at 48 is preservation and slowing the trajectory, not reversal, and the chondrocyte signaling mechanism is most effective before significant cartilage loss. Protocol: 5 mg/day SC for 10 days, twice per year (spring and autumn). If you want to push to 3 courses, you can, but 2 is the baseline. Stack-wise, two additions worth considering: First, BPC-157 is complementary — Sigumir handles the chondrocyte gene expression side, BPC-157 handles local tissue repair and tendon healing (especially relevant if you have any tendon involvement in the knee). They don't interact and can be run concurrently. Second, look at Bonomarlot in your autumn run — bone marrow support matters for the joint-adjacent bone remodeling. On the training side: joint loading matters for cartilage nutrition (it's avascular, relying on compression-driven fluid exchange). Keep training. The worst thing for early knee wear is immobility.
CONTINUE IN THE APP
Open PepperLedger to ask the Coach about Sigumir and structural longevity protocols →
Free to join. The Coach understands the full Khavinson bioregulator system and can help you build a joint and structural aging protocol.
Free to join · No credit card · 23-day Pro trial included